A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis <i>in vivo</i>
Parisa Khalili(McGill University Health Centre), Shafaat A. Rabbani(McGill University Health Centre)
Cited by 197
Related Papers
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
|Frontiers in Oncology|2018|479
Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis <i>In vitro</i> and <i>In vivo</i>
|Cancer Research|2006|155
DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications
|Frontiers in Oncology|2019|118
Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition
|Experimental & Molecular Medicine|2024|13